KDMN News and Press, Kadmon Holdings Inc. From 05/06/21

Kadmon (KDMN): Q1 GAAP EPS of -$0.17 beats by $0.01.Revenue of $0.56M (-91.7% Y/Y) misses by $0.13M.Press Release For further details see: Kadmon EPS beats by $0.01, misses on revenue

NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2021. "We continue to ramp up commercial launch preparation activities for belumosudil in anticipation of th...

Kadmon Holdings (KDMN) announces the publication of results from KD025-208, the Phase 2a clinical trial of belumosudil ((KD025)) for chronic graft-versus-host disease ((cGVHD)).Results from KD025-208, the open-label, Phase 2a clinical trial of belumosudil, which enrolled 54 cGVHD patients who...

NEW YORK, NY / ACCESSWIRE / April 21, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the publication of results from KD025-208, the Phase 2a clinical trial of belumosudil (KD025) for chronic graft-versus-host disease (cGVHD). The results were published in the Journal of Clinical...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Apri...

NEW YORK, April 06, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Kadmon Holdings, Inc. (“Kadmon” or the “Company”) (NASDAQ: KDMN) in the United States District Court for the Eastern District o...

NEW YORK, NY / ACCESSWIRE / April 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the first patient has been dosed in an open-label Phase 2 clinical trial of belumosudil, the Company's ROCK2 inhibitor, in patients with diffuse cutaneous systemic sclerosis (dcSSc), a chroni...

Should You Buy Penny Stocks This Week? If you’re looking for penny stocks to buy before April, you’ve got 3 days left. This week marks the end of Q1 2021 and the start of a brand new month and quarter heading into April. With the way the market has been lately, it’s...

NEW YORK, NY / ACCESSWIRE / March 25, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present a trial-in-progress poster on KD033-101, the Company's ongoing dose-escalation, dose-expansion trial of KD033 in patients with metastatic and locally advanced solid tumors, at the...

The following slide deck was published by Kadmon Holdings, Inc. in conjunction with this event. For further details see: Kadmon Holdings (KDMN) Presents At Oppenheimer 31st Annual Healthcare Conference - Slideshow